Emergent Biosolutions EBS Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's interest expense?
- Emergent Biosolutions (EBS) reported interest expense of $11M in Q1 2026.
- How has Emergent Biosolutions's interest expense changed year-over-year?
- Emergent Biosolutions's interest expense decreased by 25.2% year-over-year, from $14.7M to $11M.
- What is the long-term trend for Emergent Biosolutions's interest expense?
- Over 4 years (2021 to 2025), Emergent Biosolutions's interest expense has grown at a 14.5% compound annual growth rate (CAGR), from $34.5M to $59.3M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.